- Home
- EWTX vs HCM Comparison
EWTX vs HCM Comparison
Compare EWTX & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- HCM
- Stock Information
- Founded
- EWTX 2017
- HCM 2000
- Country
- EWTX United States
- HCM Hong Kong
- Employees
- EWTX N/A
- HCM N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- EWTX Health Care
- HCM Health Care
- Exchange
- EWTX Nasdaq
- HCM Nasdaq
- Market Cap
- EWTX 2.7B
- HCM 2.3B
- IPO Year
- EWTX 2021
- HCM N/A
- Fundamental
- Price
- EWTX $27.07
- HCM $16.11
- Analyst Decision
- EWTX Buy
- HCM Hold
- Analyst Count
- EWTX 7
- HCM 1
- Target Price
- EWTX $42.71
- HCM $19.00
- AVG Volume (30 Days)
- EWTX 981.1K
- HCM 73.5K
- Earning Date
- EWTX 02-28-2025
- HCM 03-19-2025
- Dividend Yield
- EWTX N/A
- HCM N/A
- EPS Growth
- EWTX N/A
- HCM N/A
- EPS
- EWTX N/A
- HCM N/A
- Revenue
- EWTX N/A
- HCM $610,806,000.00
- Revenue This Year
- EWTX N/A
- HCM N/A
- Revenue Next Year
- EWTX N/A
- HCM $15.89
- P/E Ratio
- EWTX N/A
- HCM N/A
- Revenue Growth
- EWTX N/A
- HCM N/A
- 52 Week Low
- EWTX $14.90
- HCM $12.84
- 52 Week High
- EWTX $38.12
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- EWTX 48.74
- HCM 68.69
- Support Level
- EWTX $24.92
- HCM $13.58
- Resistance Level
- EWTX $29.14
- HCM $13.96
- Average True Range (ATR)
- EWTX 1.64
- HCM 0.31
- MACD
- EWTX 0.01
- HCM 0.34
- Stochastic Oscillator
- EWTX 38.67
- HCM 89.84
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.